Decheng Capital Management III (Cayman)’s Pacific Biosciences PACB Stock Holding History

Decheng Capital Management III (Cayman)’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$12.2M	Hold	1,463,872	–	–	4.08%	9
2023 Q2	$19.5M	Hold	1,463,872	–	–	6.11%	5
2023 Q1	$17M	Hold	1,463,872	–	–	6.84%	5
2022 Q4	$12M	Hold	1,463,872	–	–	4.48%	9
2022 Q3	$8.51M	Hold	1,463,872	–	–	3.08%	10
2022 Q2	$6.47M	Hold	1,463,872	–	–	2.45%	13
2022 Q1	$13.3M	Buy	+1,463,872	New	+$16.9M	4.08%	8

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Madrone Advisors Menlo Park, California $1.39B AUM 10.34% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Decheng Capital Management III (Cayman)'s PACB Position: Q3 2023 in Review

Decheng Capital Management III (Cayman) held its Pacific Biosciences (PACB) position steady in Q3 2023 at 1,463,872 shares worth $12.2M. The position accounts for 4.08% of the portfolio, ranked #9.

Decheng Capital Management III (Cayman) first reported a position in PACB in Q1 2022 and has held it in 7 quarters since. The position peaked at $19.5M in Q2 2023. 273 funds tracked by Wall St. Rank hold PACB as of Q3 2023.

Decheng Capital Management III (Cayman) held 1,463,872 shares of Pacific Biosciences worth $12.2M as of Q3 2023.
Decheng Capital Management III (Cayman) left its Pacific Biosciences share count unchanged in Q3 2023.
Pacific Biosciences made up 4.08% of Decheng Capital Management III (Cayman)'s portfolio in Q3 2023, its #9 holding.
Decheng Capital Management III (Cayman) first reported a position in Pacific Biosciences in Q1 2022 and has held it in 7 quarters since.
Decheng Capital Management III (Cayman)'s Pacific Biosciences position peaked at $19.5M in Q2 2023.
273 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2023.

Based on Decheng Capital Management III (Cayman)'s 13F filing for Q3 2023, filed 13 Nov 2023.